Zhongnan Hospital

This phase II trial tests a chemotherapy regimen called FULIRI, combined with either bevacizumab or cetuximab, as a first treatment for colorectal cancer that has spread to the liver. The goal is to shrink the liver tumors enough so they can be surgically removed. The study will …

This phase II trial tests a combination of two drugs—Utidelone and Toripalimab—in people with recurrent or metastatic cervical cancer that has stopped responding to standard treatments. All 32 participants will receive the same treatment, and doctors will monitor tumor shrinkage …

This phase 2 trial tests whether adding an immunotherapy drug (iparomlimab and tuvonralimab) to standard chemoradiotherapy before surgery can improve outcomes for people with locally advanced rectal cancer. About 108 participants will be randomly assigned to receive either the st…

This study tests a new radioactive imaging agent called 68Ga-SFB6-ZN01, which is designed to attach to a protein found on many cancer cells. 98 adults with confirmed or suspected cancer will receive a single injection of the agent and then have a PET/CT scan. The goal is to see i…

This study will test a new imaging agent called 68Ga-B6FA-01, which targets two different markers on cancer cells and their surroundings. The goal is to see if this probe can improve PET/CT scans for diagnosing and staging solid tumors. About 100 adults with newly diagnosed or re…

This study tests a non-invasive device called Temporal Interference Stimulation (TIS) to see if it can improve movement in people with Parkinson's disease. The device uses electrical fields to stimulate deep brain areas without surgery. Twenty-four adults with mild to moderate Pa…

This study explores whether tracking rapid changes in kidney function right after a kidney transplant can help doctors choose the right dose of anti-infective drugs. Currently, dosing relies on static tests that may not reflect the fast shifts in kidney performance during the fir…